These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 19318113)

  • 1. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease.
    Robinson E; Grieve DJ
    Pharmacol Ther; 2009 Jun; 122(3):246-63. PubMed ID: 19318113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atherosclerosis and cardiovascular risk reduction with PPAR agonists.
    Kuusisto J; Andrulionyte L; Laakso M
    Curr Atheroscler Rep; 2007 Oct; 9(4):274-80. PubMed ID: 18173954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease.
    Wagner N; Wagner KD
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring biomarkers to assess the therapeutic effects of PPAR agonists?
    Chinetti-Gbaguidi G; Staels B
    Pharmacogenomics; 2007 Nov; 8(11):1567-80. PubMed ID: 18034622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review.
    Grygiel-Górniak B
    Nutr J; 2014 Feb; 13():17. PubMed ID: 24524207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPAR ligands: are they potential agents for cardiovascular disorders?
    Balakumar P; Rose M; Singh M
    Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic roles of peroxisome proliferator-activated receptor agonists.
    Staels B; Fruchart JC
    Diabetes; 2005 Aug; 54(8):2460-70. PubMed ID: 16046315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists].
    Jouzeau JY; Moulin D; Koufany M; Sebillaud S; Bianchi A; Netter P
    J Soc Biol; 2008; 202(4):289-312. PubMed ID: 19094928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
    Brown JD; Plutzky J
    Circulation; 2007 Jan; 115(4):518-33. PubMed ID: 17261671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
    Aleshin S; Grabeklis S; Hanck T; Sergeeva M; Reiser G
    Mol Pharmacol; 2009 Aug; 76(2):414-24. PubMed ID: 19483106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases.
    Sertznig P; Seifert M; Tilgen W; Reichrath J
    Am J Clin Dermatol; 2008; 9(1):15-31. PubMed ID: 18092840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges.
    Cheang WS; Tian XY; Wong WT; Huang Y
    Br J Pharmacol; 2015 Dec; 172(23):5512-22. PubMed ID: 25438608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases.
    Maccallini C; Mollica A; Amoroso R
    Am J Cardiovasc Drugs; 2017 Aug; 17(4):273-281. PubMed ID: 28315197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels.
    Yessoufou A; Wahli W
    Swiss Med Wkly; 2010; 140():w13071. PubMed ID: 20842602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus.
    Jay MA; Ren J
    Curr Diabetes Rev; 2007 Feb; 3(1):33-9. PubMed ID: 18220654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PPAR family and its relationship to metabolic syndrome].
    Zhang XY; Chen LH; Guan YF
    Sheng Li Ke Xue Jin Zhan; 2005 Jan; 36(1):6-12. PubMed ID: 15881336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [PPAR and diabetes].
    Terauchi Y; Kadowaki T
    Nihon Rinsho; 2005 Apr; 63(4):623-9. PubMed ID: 15828230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.